Form 8-K

8-K — Theravance Biopharma, Inc.

Accession: 0001104659-26-056733

Filed: 2026-05-07

Period: 2026-05-07

CIK: 0001583107

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tm2613884d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2613884d1_ex99-1.htm)

GRAPHIC (tm2613884d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2613884d1_8k.htm · Sequence: 1

false

0001583107

2026-05-07

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported):

May 7, 2026

THERAVANCE

BIOPHARMA, INC.

(Exact Name of Registrant as Specified in its

Charter)

Cayman Islands

001-36033

98-1226628

(State

or Other Jurisdiction of

(Commission

File Number)

(I.R.S.

Employer Identification

Incorporation)

Number)

c/o Theravance Biopharma US, LLC

901

Gateway Boulevard

South

San Francisco, CA 94080

(650)

808-6000

(Addresses, including zip code, and telephone

numbers, including area code, of principal executive offices)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General

Instruction A.2. below):

Written communications pursuant

to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to

Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Ordinary

Share $0.00001 Par Value

TBPH

NASDAQ

Global Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company    ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On May 7, 2026, Theravance Biopharma, Inc. (the “Company”)

issued a press release regarding its financial results for the quarter ended March 31, 2026, and a business update. A copy of the press

release is furnished as Exhibit 99.1 to this Current Report.

The information in Item 2.02 and in Item 9.01 of this Current Report

on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of

the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act of 1934”), or otherwise subject to the liabilities

of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities

Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1

Press Release dated May 7, 2026

104

Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THERAVANCE BIOPHARMA, INC.

Date: May 7, 2026

By:

/s/ Aziz Sawaf

Aziz Sawaf

Senior Vice President and Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2613884d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Theravance Biopharma,

Inc. Reports First Quarter 2026

Financial Results and Provides Corporate Update

· YUPELRI® Collaboration Revenue increased 15% year-over-year1,

from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage

· All Hatch-Waxman litigation relating to YUPELRI® has been

resolved following settlement with Mankind Pharma in March

· Organizational restructuring and cost reduction initiatives on track; delivered ~20% reduction in Operating Expenses year-over-year

(excluding restructuring items)

· Q1 2026 TRELEGY net sales, reported by GSK, of $873 million, up 2% year-over-year; high confidence in achieving the $100 million

2026 milestone payment2

· Strategic Review Committee actively evaluating a range of opportunities to maximize shareholder value

· Quarter-end cash balance of $395 million and no debt

DUBLIN,

IRELAND – May 7, 2026 – Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”)

(NASDAQ: TBPH) today reported financial and operational results for the first quarter of 2026.

"We

delivered strong financial performance in the first quarter, reinforcing the quality of our commercial asset, our robust balance sheet

and the important actions underway to reshape our cost structure, following the outcome of the CYPRESS study,” said

Rick E Winningham, Chief Executive Officer of Theravance Biopharma. “YUPELRI® continues to deliver sustained net

sales growth and expanding profitability, supported by growing community and hospital adoption, improved net pricing, and the recent resolution

of generic litigation, driving increased long-term value for the franchise. TRELEGY also continued to perform well, and we remain confident

that we will achieve the $100 million milestone payment associated with 2026 net sales. The entire Theravance team is acting with discipline

and urgency, and we are confident that the continued execution against our strategic priorities and the Board’s ongoing review process

will maximize value for shareholders."

Strategic Review Committee

In 2024, the Theravance

Board of Directors formed a Strategic Review Committee (the “Committee”) composed entirely of independent directors to assess

all strategic alternatives available to the Company. Since then, the Committee has been working on an ongoing basis with Lazard, its independent

financial advisor, to evaluate opportunities to maximize shareholder value, including under multiple potential outcomes for the

CYPRESS study, which the Company announced on March 3rd did not meet the primary endpoint. Building upon this work, the Committee

is acting with urgency to evaluate a broad range of value maximizing and tax efficient alternatives, including but not limited to a sale

of the Company. In connection with the Company’s March 3rd announcement to wind down the ampreloxetine program and implement

an organizational restructuring, the Committee has accelerated its evaluation of strategic alternatives for the Company. There can be

no assurance that the Committee’s strategic review process will result in any transaction. Theravance Biopharma does not intend

to disclose further developments on this review process unless and until it determines that such disclosure is appropriate or necessary.

1 In the U.S., Viatris is leading the commercialization

of YUPELRI, and the Company co-promotes the product under a profit and loss sharing arrangement (65% to Viatris; 35% to the Company).

2 Payment from Royalty Pharma (RP) will be triggered if

RP receives certain minimum royalty payments from GSK based on TRELEGY global net sales.

Page 1 of 9

Operational Highlights

YUPELRI®

(revefenacin) inhalation solution, the first and only once-daily, nebulized LAMA (long-acting muscarinic antagonist) bronchodilator approved

in the U.S. for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD):

· Quarterly U.S. net sales of $62.4 million, recognized by Viatris, in Q1 2026,

increasing 7% year-over-year (YoY) (Q1 2026 vs Q1 2025)1 driven by customer demand growth of 4% YoY (Q1 2026 vs Q1 2025)3,

consistent with typical first quarter seasonality, and improved net pricing.

· Increased doses pulled through the hospital channel by 19% YoY (Q1 2026 vs

Q1 2025), reflecting another excellent quarter of growth.4

· Theravance and Viatris (Mylan) entered into a settlement in March with Mankind

Pharma Ltd. with a licensed launch date of April 23, 2039, subject to certain exceptions and other provisions customary for agreements

of this type.

o With this settlement agreement, all Hatch-Waxman litigation relating to YUPELRI®

(revefenacin) inhalation solution has been resolved.

TRELEGY

GSK reported first quarter 2026 global

net sales of $873 million (up 2% vs. the first quarter of 2025)5:

· FY 2025 global net sales of approximately $3.9 billion triggered a $50M milestone

payment from Royalty Pharma, with cash received in February 2026.

· FY 2026 global net sales of ~$3.5 billion required to trigger an additional

$100M milestone payment from Royalty Pharma.

Organizational Restructuring Update

· Following the announcement of the Company’s Phase 3 CYPRESS results

in March, Theravance has made progress on its organizational restructuring.

· As an early indicator of this progress, Operating Expenses (excluding restructuring

costs) decreased approximately 20% year-over-year in Q1 2026 compared to Q1 2025, with more material reductions expected in Q2 2026 and

full run-rate savings anticipated beginning in Q3 2026.

3 Source: Viatris Customer Demand (Q1’26).

4 Source: IQVIA DDD, HDS, VA and Non-Reporting Hospital

through Mar ’26.

5 GSK-reported Net Sales in USD.

Page 2 of 9

· The Company reaffirms it is on track to reduce operating expenses by approximately

60%, resulting in approximately $60 - $70 million of annualized cash flow, with the full benefit expected to be realized beginning in

the third quarter of 2026.

First Quarter Financial Results

· Revenue: Total revenue for the first quarter of 2026 was $17.7 million,

consisting entirely of Viatris collaboration revenue. Viatris collaboration revenue increased by $2.3 million, or 15%, in the first quarter

compared to the same period in 2025. The Viatris collaboration revenue represents amounts receivable from Viatris and comprises the Company’s

35% share of net sales of YUPELRI, as well as its proportionate amount of the total shared commercial costs incurred by the two companies.

The non-shared YUPELRI costs incurred by Theravance Biopharma are recorded within operating expenses. While Viatris records the total

net sales of YUPELRI within its financial statements, Theravance Biopharma’s implied 35% share of net sales of YUPELRI for the first

quarter of 2026 was $21.9 million which represented a 7% increase compared to the same period in 2025.

· Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2026 were $5.8 million, compared to

$11.5 million in the same period in 2025. The reduction was driven by the corporate restructuring announced in March 2026 and ongoing

wind-down of the CYPRESS clinical trial. First quarter R&D expenses included total non-cash share-based compensation of $0.6 million.

· Selling, General and Administrative (SG&A) Expenses: SG&A expenses for the first quarter of 2026 were $17.7 million,

compared to $18.4 million in the same period in 2025. First quarter SG&A expenses included total non-cash share-based compensation

of $2.9 million.

· Restructuring Expenses: Restructuring expenses for the first quarter of 2026 were $3.6 million and were comprised of severance

costs and termination-related benefits. Cash restructuring costs were $2.6 million and non-cash restructuring costs were $1.0 million.

· Share-Based Compensation: Total share-based compensation expenses

for the first quarter of 2026 were $4.5 million which included restructuring-related share-based compensation expense. Excluding restructuring-related

expenses, share-based compensation was $3.5 million, compared to $4.9 million in the same period in 2025. Share-based compensation expenses

for the first quarter of 2026 consisted of $0.6 million for R&D, $2.9 million for SG&A, and $1.0 million related to the restructuring.

· Net Loss: Net loss was $4.9 million in the first quarter of 2026 compared

to a net loss of $13.6 million in the same period in 2025.

Page 3 of 9

· Non-GAAP Net Income (Loss) from Operations6:

Non-GAAP net income from operations was $0.6 million in the first quarter of 2026 compared to a non-GAAP net loss from operations of $8.6

million in the same period in 2025. See the section titled "Non-GAAP Financial Measures" for more information.

· Cash Position: Cash, cash equivalents and marketable securities totaled

$394.7 million as of March 31, 2026. The Company received a $25.0 million YUPELRI U.S. sales milestone from Viatris in January 2026 and

a $50.0 million TRELEGY milestone from Royalty Pharma in February 2026.

· Shares Outstanding: The Company had 51,514,968 ordinary shares outstanding

as of March 31, 2026.

2026 Financial Guidance

Theravance

Biopharma is implementing an organizational restructuring to streamline costs and align its resources with its commercial focus on YUPELRI.

The restructuring will involve winding down the R&D function and significantly reducing the G&A function. The restructuring

is expected to reduce operating expenses by approximately 60%, relative to 2025 actuals of $111.1 million. The full run-rate cost savings

of approximately $70 million are expected to fully materialize in the third quarter of 2026.

Together, the cost savings from the restructuring

and continued sales from YUPELRI are expected to result in the Company generating approximately $60 to $70 million of annualized cash

flow, starting in the third quarter of 2026. This cash flow projection is comprised of an estimated $45 to $55 million of Income from

Operations (excluding non-cash share-based compensation) and projected Interest and Other Income, and does not include potential income

from the $100 million TRELEGY milestone.

The restructuring is expected to impact approximately

50% of the overall workforce. This reduction includes the wind-down of the R&D organization and a decrease of approximately 50% in

G&A employees. These actions are expected to be implemented over the next two quarters, and the Company expects to incur approximately

$5 to $7 million in one-time cash severance costs related to these actions.

Conference Call

Beginning last quarter, earnings results are being released via press

release only. The Company will not host a conference call or webcast to discuss quarterly results.

6 Non-GAAP profit (loss) consists of GAAP net income (loss)

before taxes less (i) share-based compensation expense, (ii) non-cash interest expense, and (iii) non-recurring revenue and income items.

See the section titled "Non-GAAP Financial Measures" for more information.

Page 4 of 9

About Theravance Biopharma

Theravance Biopharma, Inc.’s focus is to

deliver Medicines that Make a Difference® in people’s lives. In pursuit of its purpose, Theravance Biopharma

leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution

indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The Company is committed to creating/driving

shareholder value.

For more information,

please visit www.theravance.com.

THERAVANCE BIOPHARMA®, THERAVANCE®

and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and

certain other countries).

YUPELRI® is a registered trademark of Viatris

Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective

owners.

Forward-Looking Statements

This press release contains certain "forward-looking" statements

as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to

goals, plans, objectives, expectations and future events. Theravance Biopharma, Inc. (the “Company”) intends such forward-looking

statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange

Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Examples of such statements

include statements relating to: the Company’s expectations regarding its future profitability, expenses and uses of cash, the Company’s

goals, designs, strategies, plans and objectives, future growth of YUPELRI sales and future royalty payments, the winddown of the Company’s

ampreloxetine program and R&D function and significant reduction of its G&A function, the consideration of strategic alternatives

for the Company, the ability to provide value to shareholders, the Company’s regulatory strategies, and contingent milestone payments

due to the Company from the sale of the Company’s TRELEGY royalty interests. These statements are based on the current estimates

and assumptions of the management of Theravance Biopharma as of the date of this press release and are subject to risks, uncertainties,

changes in circumstances, assumptions and other factors that may cause the actual results of Theravance Biopharma to be materially different

from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those

indicated by such forward-looking statements include, among others, risks related to: factors that could increase the Company’s

expenses beyond its expectations and any factors that could adversely affect its profitability, whether the TRELEGY milestone thresholds

will be achieved, delays or difficulties in winding down clinical studies, the timing of any potential strategic transaction with respect

to the Company, if at all, risks of collaborating with or relying on third parties to develop, manufacture and commercialize products,

and risks associated with establishing and maintaining sales, marketing and distribution capabilities with appropriate technical expertise

and supporting infrastructure, the ability of the Company to protect and to enforce its intellectual property rights, volatility and fluctuations

in the trading price and volume of the Company’s shares, and general economic and market conditions. Other risks affecting the Company

are in the Company’s Form 10-K filed with the SEC on March 23, 2026, and other periodic reports filed with the SEC. In addition

to the risks described above and in Theravance Biopharma's filings with the SEC, other unknown or unpredictable factors also could affect

Theravance Biopharma’s results. No forward-looking statements can be guaranteed, and actual results may differ materially from such

statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance Biopharma assumes

no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by

law.

Page 5 of 9

Non-GAAP Financial Measures

Theravance Biopharma provides a non-GAAP metric in this press release.

Theravance Biopharma believes that non-GAAP net income (loss) provides meaningful information to assist investors in assessing prospects

for future performance and actual performance as they provide better metrics for analyzing the performance of its business by excluding

items that may not be indicative of core operating results and the Company's cash position. Because non-GAAP financial targets and metrics,

such as non-GAAP net income (loss), are not standardized, it may not be possible to compare these measures with other companies' non-GAAP

targets or measures having the same or a similar name. Thus, Theravance Biopharma's non-GAAP measures should be considered in addition

to, not as a substitute for, or in isolation from, the Company's actual GAAP results and other targets.

Please see the appendix attached to this press release for a reconciliation

of non-GAAP net income (loss) to its corresponding measure, net income (loss). A reconciliation of non-GAAP net income (loss) to its corresponding

GAAP measure is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding, and the potential

variability of, expenses and other factors in the future.

Contact:

investor.relations@theravance.com

650-808-4045

Page 6 of 9

THERAVANCE BIOPHARMA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

March 31,

December 31,

2026

2025

(Unaudited)

(1)

Assets

Current assets:

Cash and cash equivalents and short-term marketable securities

$ 394,666

$ 315,357

Receivables from collaborative arrangements

15,584

45,539

Receivables from milestone and royalty assets

50,000

Other prepaid and current assets

7,384

7,564

Total current assets

417,634

418,460

Long-term marketable securities

11,128

Property and equipment, net

5,539

5,895

Operating lease assets

23,001

24,371

Restricted cash

836

Other assets

25,303

24,880

Total assets

$ 472,313

$ 485,570

Liabilities and Shareholders' Equity

Current liabilities

$ 31,775

$ 38,302

Long-term operating lease liabilities

29,752

31,758

Future royalty payment contingency

32,795

Unrecognized tax benefits

87,153

85,679

Other long-term liabilities

244

313

Shareholders' equity

290,594

296,723

Total liabilities and shareholders’ equity

$ 472,313

$ 485,570

(1) The

condensed consolidated balance sheet as of December 31, 2025 has been derived from the audited consolidated financial statements

included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

Page 7 of 9

THERAVANCE BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

Three Months Ended March 31,

2026

2025

(Unaudited)

Revenue:

Viatris collaboration agreement (1)

$ 17,699

$ 15,388

Total revenue

17,699

15,388

Costs and expenses:

Research and development (2)

5,829

11,452

Selling, general and administrative (2)

17,720

18,370

Restructuring expenses (2) (3)

3,633

Total costs and expenses

27,182

29,822

Loss from operations

(9,483 )

(14,434 )

Interest expense (non-cash)

(643 )

Interest income and other income, net

3,013

939

Loss before income taxes

(6,470 )

(14,138 )

Provision for income tax benefit

1,537

559

Net loss

$ (4,933 )

$ (13,579 )

Net loss per share:

Net loss per share - basic and diluted

$ (0.10 )

$ (0.27 )

Shares used to compute net loss per share - basic and diluted

51,279

49,706

Non-GAAP net income (loss)

$ 639

$ (8,618 )

(1)

While Viatris, Inc. records the total YUPELRI net sales, the Company is entitled to a 35% share of the net profit (loss) pursuant to

a co-promotion agreement with Viatris as presented below:

Three Months Ended March 31,

(In thousands)

2026

2025

YUPELRI net sales (100% recorded by Viatris)

$ 62,430

$ 58,344

YUPELRI net sales (Theravance Biopharma implied 35%)

21,851

20,420

(2) Amounts include share-based compensation expense as follows:

Three Months Ended March 31,

(In thousands)

2026

2025

Research and development

$ 627

$ 1,070

Selling, general and administrative

2,849

3,807

Restructuring expenses

1,028

Total share-based compensation expense

$ 4,504

$ 4,877

(3)

Restructuring expenses were comprised of:

Three Months Ended March 31,

(In thousands)

2026

2025

Cash-related expenses

$ 2,605

$ -

Non-cash related expenses

1,028

Total restructuring expenses

$ 3,633

$ -

Page 8 of 9

THERAVANCE BIOPHARMA, INC.

Reconciliation of GAAP Net Loss to Non-GAAP Net Income (Loss)

(In thousands)

Three Months Ended March 31,

2026

2025

(Unaudited)

GAAP net loss

$ (4,933 )

$ (13,579 )

Adjustments:

Share-based compensation expense

4,504

4,877

Non-cash interest expense

643

Income tax benefit

(1,537 )

(559 )

Restructuring expense (excl. share-based compensation)

2,605

Non-GAAP net income (loss)

$ 639

$ (8,618 )

Page 9 of 9

GRAPHIC

Filename: tm2613884d1_ex99-1img001.jpg · Sequence: 6

Binary file (4172 bytes)

Download tm2613884d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

May 07, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 07, 2026

Entity File Number

001-36033

Entity Registrant Name

THERAVANCE

BIOPHARMA, INC.

Entity Central Index Key

0001583107

Entity Tax Identification Number

98-1226628

Entity Incorporation, State or Country Code

Entity Address, Address Line One

c/o Theravance Biopharma US, LLC

Entity Address, Address Line Two

901

Gateway Boulevard

Entity Address, City or Town

South

San Francisco

Entity Address, Country

Entity Address, Postal Zip Code

94080

City Area Code

650

Local Phone Number

808-6000

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Ordinary

Share $0.00001 Par Value

Trading Symbol

TBPH

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration